Eribulin Mesylate 1mg
| Product Overview | |
| Generic Name | Eribulin Mesylate 1mg |
| Brand Name(s) | Halaven® |
| Form | Sterile injectable solution; single-dose vial |
| Strength | 1 mg/2 mL; 0.5 mg/mL. |
| Therapeutic Class | Microtubule inhibitor / tubulin-based antimitotic agent |
| ATC Code | L01XX41 |
| Manufacturing & Regulatory | |
| Manufacturer | Eisai, Lupin/Natco/Glenmark |
| Country | Japan, Mexico, USA/India |
| GMP Compliance | WHO-GMP |
| COFEPRIS | 010.000.6082.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 24 Months |
| Storage | 15–30°C; do not freeze or refrigerate |
| Incoterms | EXW, HS 30049049 |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes—lot-specific Certificate of Analysis |
| SDS | Required as cytotoxic hazardous drug SDS |
| CTD Summary | CTD proprietary; available under commercial agreement/license |
Description
Eribulin Mesylate is indicated for adults with metastatic breast cancer after prior chemotherapy and for unresectable/metastatic liposarcoma after prior anthracycline therapy.
